Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Monopar Therapeutics Inc (NQ: MNPR ) 13.49 -1.18 (-8.05%) Streaming Delayed Price Updated: 2:07 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Monopar Therapeutics Inc < Previous 1 2 Next > Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock October 28, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock October 28, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire MarketBeat Week in Review – 10/21- 10/25 October 26, 2024 Equities had a mixed week, but the tech-heavy NASDAQ powered to an all-time high; big tech earnings and key economic reports could bring more volatility Via MarketBeat Topics Artificial Intelligence Economy Stocks Exposures Artificial Intelligence Economy Interest Rates Monopar Therapeutics Skyrockets 400% on Licensing Deal October 25, 2024 Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug. Via MarketBeat Exposures COVID-19 Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate October 24, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 October 22, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers October 15, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers October 07, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr September 12, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference September 04, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule August 27, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers August 21, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr August 14, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments August 09, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Therapeutics Announces 1-for-5 Reverse Stock Split August 09, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr July 09, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24 June 25, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar and NorthStar Amend & Extend Collaboration June 11, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting June 10, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces CFO Succession May 24, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline May 09, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting April 18, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings April 16, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients April 10, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments March 28, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program March 05, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial February 27, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers February 22, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers February 20, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments November 09, 2023 MNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual... From Monopar Therapeutics Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
